Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of randomised trials

Diabetologia

Volumn 55, Issue 4, 2012, Pages 885-904

  Musso, G ^a   Cassader, M ^b   Rosina, F ^a   Gambino, R ^b  

^a GRADENIGO HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Fatty liver; Human; Management; Meta analysis; NAFLD; NASH; Systematic review

Indexed keywords

ADIPONECTIN; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; ATORVASTATIN; BILE ACID; C REACTIVE PROTEIN; CARNITINE; DNA FORMAMIDOPYRIMIDINE GLYCOSYLASE; EZETIMIBE; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIRAGLUTIDE; METFORMIN; NIVOCASAN; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PIOGLITAZONE; PROBIOTIC AGENT; PROBUCOL; RIMONABANT; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ABDOMINAL OBESITY; AEROBIC EXERCISE; ANKLE EDEMA; ANXIETY DISORDER; BLOOD PRESSURE REGULATION; CALORIC RESTRICTION; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CONGESTIVE HEART FAILURE; DEPRESSION; DIABETES MELLITUS; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FATTY LIVER; FRACTURE; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HEPATITIS; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER FIBROSIS; LIVER HISTOLOGY; LOW CARBOHYDRATE DIET; LOW FAT DIET; MENTAL DISEASE; META ANALYSIS (TOPIC); NERVOUS SYSTEM INFLAMMATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; WAIST CIRCUMFERENCE; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

CARDIOVASCULAR DISEASES; FATTY LIVER; GLUCOSE; HUMANS; LIVER DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 84862517200     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2446-4     Document Type: Review

References (140)

1. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G (2010) A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 53:372-384
2. Younossi ZM, Stepanova M, Afendy M et al (2011) Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 9:524-530
3. Musso G, Gambino R, Cassader M, Pagano G (2011) Prognosis and non-invasive methods to assess liver disease severity in non-alcoholic fatty liver disease (NAFLD): systematic review and meta-analysis. Ann Med 43:617-649
4. Ghouri N, Preiss D, Sattar N (2010) Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 52:1156-1161
5. Higgins JPT, Green S (eds) (2008) Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.0. The Cochrane Collaboration. Available at www.Cochrane-handbook.org. Accessed 26 May 2009
6. Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ (2003) Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 38:413-419
7. Zelber-Sagi S, Kessler A, Brazowsky E et al (2006) A double-blind randomized placebo-controlled trial of orlistat for the treatment of non-alcoholic fatty liver disease. Clin Gastroenterol Hepatol 4:639-644
8. Lazo M, Solga SF, Horska A et al (2010) The effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 33:2156-2163
9. Shah K, Stufflebaum A, Hilton TN et al (2009) Diet and exercise intervention reduce intrahepatic fat content and improve insulin sensitivity in obese adult older adults. Obesity 17:2162-2168
10. Promrat K, Kleiner DE, Niemeier HM et al (2010) Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51:121-129
11. Nobili V, Manco M, Devito R et al (2008) Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology 48: 119-128
12. Harrison SA, Brunt EM, Fecht WJ, Neuschwander-Tetri BA (2009) Orlistat for overweight subjects with nonalcoholic steato-hepatitis (NASH): a randomized prospective trial. Hepatology 49:80-86
13. Hayward CS, Lockwood J, Williams CD, Cole RE, Torres DM, Harrison SA (2010) Lifestyle modification and NAFLD: a prospective randomized trial. Hepatology 52(S4):622A
14. Kistler K, Brunt EM, Clark JM et al (2011) Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol 106:460-468
15. Perseghin G, Lattuada G, de Cobelli F et al (2007) Habitual physical activity is associated with intrahepatic fat content in humans. Diabetes Care 30:683-688
16. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R et al (2008) Role of leisure-time physical activity in non-alcoholic fatty liver disease; a population-based study. Hepatology 48:1791-1798
17. Rabøl R, Falk Petersen K, Dufour S, Flannery C S, Shulman GL (2011) Reversal of muscle insulin resistance with exercise reduces postprandial hepatic de novo lipogenesis in insulin resistant individuals. Proc Natl Acad Sci USA 108:13705-13709
18. Bonekamp S, Barone BB, Clark J, Stewart KJ (2008) The effects of an exercise training intervention on hepatic steatosis. Hepatology 48(Suppl 1):806A
19. Johnson NA, Sachinwalla T, Walton DW et al (2009) Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 50:1105-1112
20. St. George A, Bauman A, Johnston A et al (2009) Independent effects of physical activity in patients with non-alcoholic fatty liver. Hepatology 50:68-76
21. Hallsworth K, Fattakhowa G, Hollingsworth K et al (2011) Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 60:1278-1283
22. Frith J, Day CP, Robinson L, Elliott C, Jones DE, Newton JL (2010) Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease. J Hepatol 52:112-116
23. Kirk E, Reeds DN, Finck BN, Mayurranjan MS, Klein S (2009) Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 136:1552-1560
24. Haufe S, Engeli S, Kast P et al (2011) Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology 53:1504-1514
25. de Luis DA, Aller R, Izaola O, Gonzalez Sagrato M, Conde R (2010) Effect of two different hypocaloric diets in transaminases and insulin resistance in nonalcoholic fatty liver disease and obese patients. Nutr Hosp 25:730-735
26. Gastaldelli A, Harrison SA, Belfort-Aguilar R et al (2009) Importance of changes in adipose tissue insulin resistance to histo-logical response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 50:1087-1093
27. Sanyal AJ, Mofrad PS, Contos MJ et al (2004) A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2:1107-1115
28. Belfort R, Harrison SA, Brown K et al (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355:2297-2307
29. Aithal GP, Thomas JA, Kaye PV et al (2008) Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135:1176-1184
30. Ratziu V, Giral P, Jacqueminet S et al (2008) Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 135:100-110
31. Idilman R, Mizrak D, Corapcioglu D et al (2008) Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 28:200-208
32. Sanyal AJ, Chalasani N, Kowdley KV et al (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 362:1675-1685
33. Omer Z, Cetinkalp S, Akyildiz M et al (2010) Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 22:18-23
34. Tiikkainen M, Häkkinen AM, Korsheninnikova E, Nyman T, Mäkimattila S, Yki-Järvinen H (2004) Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53:2169-2173
35. Jonker JT, Wang Y, de Haan W et al (2010) Pioglitazone decreases plasma cetp mass, associated with a decrease in hepatic triglyceride content, in patients with type 2 diabetes mellitus. Diabetes Care 33:1625-1628
36. Shah PK, Mudaliar S, Chang AR et al (2011) Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes. Diabetes Obes Metabol 13:505-510
37. Gupta AK, Bray GA, Greenway FL et al (2010) Pioglitazone, but not metformin, reduces liver fat in type-2 diabetes mellitus independent of weight changes. J Diabetes Complications 24:289-296
38. Torres D, Jones F, Shaw J, Williams C, Ward J, Harrison S (2011) Rosiglitazone versus rosiglitazone and metformin versus rosiglita-zone and losartan in the treatment of nonalcoholic steatohepatitis (NASH): a 12 month-randomized, prospective, open-label trial. Hepatology. doi:10.1002/hep.24558
39. Lutchamn G, Modi A, Kleiner DE et al (2007) The effects of discontinuing pioglitazone in patients with non-alcoholic steato-hepatitis. Hepatology 46:424-429
40. Ratziu V, Charlotte F, Bernhardt C et al (2010) Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the FLIRT-2 extension trial. Hepatology 51:445-453
41. Zhou G, Myers R, Li Y et al (2001) Role of AMP-activated protein kinase in mechanisms of metformin action. J Clin Invest 108:1167-1174
42. Uygun A, Kadayifci A, Isik AT et al (2004) Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 19:537-544
43. Haukeland JW, Konopski Z, Beate Eggesbø H et al (2009) Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 44:853-860
44. Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ (2009) The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial. Ther Adv Gastroenterology 2:157-163
45. Bugianesi E, Gentilcore E, Manini R et al (2005) A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 100: 1082-1090
46. Nar A, Gedik O (2009) The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetol 46:113-118
47. Garinis GA, Fruci B, Mazza A et al (2010) Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes (Lond). doi:10.1038/ijo.2010.40
48. Tock L, Dâmaso AR, de Piano A et al (2010) Long-term effects of metformin and lifestyle modification on nonalcoholic fatty liver disease obese adolescents. J Obes. doi:10.1155/2010/831901
49. Lavine JE, Schwimmer JB, van Natta ML et al (2011) Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 305:1659-1668
50. Sofer E, Boaz M, Matas Z, Mashavi M, Shargorodsky M (2011) Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. Metabolism 60:1278-1284
51. Cohen DE, Anania FA, Chalasani N (2006) An assessment of statin safety by hepatologists. Am J Cardiol 97(8A):77C-81C
52. Sattar N, Preiss D, Murray HM et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375:735-742
53. Athyros VG, Mikhailidis DP, Didangelos TP et al (2006) Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 22:873-883
54. Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD (2011) Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol 106:71-77
55. Athyros VG, Tziomalos K, Gossios TD et al (2010) Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 376:1916-1922
56. Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA (2009) A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol 43:990-994
57. Wouters K, van Gorp PJ, Bieghs V et al (2008) Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of NASH. Hepatology 48: 474-486
58. Yasutake K, Nakamuta M, Shima Y et al (2009) Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scand J Gastro-enterol 44:471-477
59. Enjoji M, Nakamuta M (2010) Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease? World J Gastroenterol 16:800-803
60. Zheng S, Hoos L, Cook J et al (2008) Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Eur J Pharmacol 584:118-124
61. Nozaki Y, Fujita K, Yoneda M et al (2009) Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. J Hepatol 51:548-556
62. Deushi M, Nomura M, Kawakami A et al (2007) Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 581:5664-5670
63. Chan DC, Watts GF, Gan SK, Ooi EM (2010) Barrett PH Effect of ezetimibe on hepatic fat, inflammatory markers and apolipo-protein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 33:1134-1139
64. Takeshita Y, Takamura T, Kita Y et al (2011) Efficacy of ezeti-mibe for the treatment of non-alcoholic fatty liver disease: a randomized controlled trial. J Hep 54:S346
65. Nobili V, Bedogni G, Alisi A et al (2011) Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child 96:350-353
66. Spadaro L, Magliocco O, Spampinato D et al (2008) Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liv Dis 40:194-199
67. Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW (2008) Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol 14:6395-6400
68. Cussons AJ, Watts GF, Mori TA, Stuckey BGA (2009) Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab 94:3842-3848
69. Caldwell SH, Argo CK, Henry TD et al (2011) Dissociated histological and metabolic effects of omega-3 (3, 000 mg/d) vs. placebo with both exercise and diet in a double-blind randomized controlled trial of NASH. J Hep 54:S8
70. Merat S, Malekzadeh R, Sohrabi MR et al (2003) Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatology 38:414-418
71. Seo YS, Kim JH, Jo NY et al (2008) PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. J Gastroenterol Hepatol 23:102-109
72. Basaranoglu M, Acbay O, Sonsuz A (1999) A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steato-hepatitis. J Hepatol 31:384
73. Conjeevaram HS, McKenna BJ, Kang H et al (2009) A randomized placebo-controlled study of PPAR-alpha agonist fenofibrate in patients with nonalcoholic steatohepatitis (NASH). Hepatology 50 (S4):774A
74. Korenblat K, Fabbrini E, Mohammed BS et al (2009) Effects of fenofibrate and long-acting nicotinic acid on intrahepatic triglyceride content and adipose tissue insulin sensitivity in obese human subjects. J Hep 50:S25
75. Fabbrini E, Mohammed BS, Korenblat KM et al (2010) Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J Clin Endocrinol Metab 95:2727-2735
76. Georgescu EF, Ionescu R, Georgescu M et al (2009) Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol 15:942-954
77. Fogari R, Mugellini A, Zoppi A et al (2011) Losartan alone or in combination with simvastatin improved visceral adipose tissue and inflammation in hypertensive normocholesterolemic patients with nonalcoholic hepatic steatosis. Eur J Gastroenterol Hepatol. doi:10.1097/MEG.0b013e32834ba188
78. Després JP, Ross R, Boka G, Alméras N, Lemieux I (2009) Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat. The ADAGIO-Lipids Trial. Arterioscler Thromb Vasc Biol 29: 416-423
79. Buranawui W, Thung-u-thaisri P, Pramoolsinsap C et al (2010) Pentoxifylline for treatment of non-alcoholic fatty liver disease (NAFLD): a randomized, placebo-controlled study. Gastroenterology A330:s2161
80. Lee YM, Sutedja D, Wai CT et al (2008) A randomized controlled pilot study of pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int 2:196-201
81. Rinella ME, Koppe S, Brunt EM, Elias M, Gottstein J, Green RM (2010) Pentoxifylline improves ALT and histology in patients with NASH: a double-blind placebo controlled trial. Gastroenterology 136 (Supplement) Digestive Disease Week (CD-ROM)
82. Zein CO, Yerian LM, Gogate P et al (2011) Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology. doi:10.1002/hep.24544
83. Santos VN, Lanzoni VP, Szejnfeld D, Shigueoka D, Parise ER (2003) A randomized double-blind study of the short-time treatment of obese patients with non-alcoholic fatty liver disease with ursodeoxycholic acid. Braz J Med Biol Res 36:723-729
84. Mendez-Sanchez N, Gonzalez V, Chavez-Tapia N, Ramos M, Uribe M (2004) Weight reduction and ursodeoxycholic acid in subjects with non-alcoholic fatty liver disease. A double-blind, placebo-controlled trial. Ann Hepatol 3:108-112
85. Ersoz G, Gunsar F, Karasu Z, Akay S, Batur Y, Akarca US (2005) Management of fatty liver disease with vitamin E and C compared to ursodeocycholic acid treatment. Turk J Gastroenterol 16:124-128
86. Ratziu V, de Ledinghen V, Oberti F et al (2011) A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol 54:1011-1019
87. Leuschner UFH, Lindenthal B, Herrmann G et al (2010) High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 52:472-479
88. Lindor KD, Kowdley KV, Heathcote EJ et al (2004) Ursodeoxy-cholic acid for the treatment of non-alcoholic steatohepatitis: results of a randomized trial. Hepatology 39:770-778
89. Dufour JF, Oneta CM, Gonvers JJ et al (2006) Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in non-alcoholic steatohepatitis. Clin Gastroenterol Hepatol 4:1537-1543
90. Musso G, Gambino R, Cassader M (2010) Emerging molecular targets for the treatment of nonalcoholic fatty liver disease. Ann Rev Med 61:375-392
91. Knop FK (2010) Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes? Am J Physiol Endocrinol Metab 299:E10-E13
92. Sanyal AJ, Mudaliar S, Henry RR et al (2010) A new therapy for non-alcoholic fatty liver disease and diabetes? Int-747-the first FXR hepatic therapeutic study. Hepatology 50:389A
93. Rui M, Wang C, Fang J et al (2001) The clinical comparison of reduced glutathione and DaiNingPlan in the treatment of nonalcoholic steatohepatitis. Chin Gen Pract 4:269-270
94. Harrison SA, Torgerson S, Ward J et al (2003) Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 98:2485-2490
95. Abdelmalek MF, Sanderson SO, Angulo P et al (2009) Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 50:1818-1826
96. Pamuk GE, Sonsuz A (2003) N-acetylcysteine in the treatment of nonalcoholic steatohepatitis. J Gastroenterol Hepatol 18:1220-1221
97. Miglio F, Rovati LC, Santoro A, Senikar I (2000) Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel group, placebo-controlled prospective clinical study. Arzneimittelforschung 50:722-727
98. Vilar Gomez E, Rodriguez de Miranda A, Gra Oramas B et al (2009) Clinical trial: Viusid(R) in combination with diet and exercise in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 30:999-1009
99. Loguercio C, Federico A, Trappoliere M et al (2007) The effect of a silybin-vitamin E-phospholipid complex on nonalcoholic fatty liver disease. Dig Dis Sci 52:2387-2395
100. Hashemi SJ, Hajiani E, Sardabi EH (2009) A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease. Hepat Mon 9:265-270
101. Neuschwander-Tetri BA, Sanyal AJ, Chalasani NP et al (2010) Changes in ALT and vitamin E levels and histological response in patients with NASH treated with vitamin E in the PIVENS trial. Hepatology 52:620A
102. Malaguarnera M, Gargante MP, Russo C et al (2010) L-Carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis. A randomized and controlled clinical trial. Am J Gastroenterol. doi:10.1038/ajg.2009.719
103. Musso G, Gambino R, Cassader M (2011) Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Ann Rev Med 62:361-380
104. Solga SF, Buckley G, Clark JM, Horska A, Diehl AM (2008) The effect of a probiotic on hepatic steatosis. J Clin Gastroenterol 42:1117-1119
105. Wong VWS, Wong GLH, Wong CH, Chan HLY (2011) Treatment of non-alcoholic steatohepatitis with probiotics\a proof-of-concept study with serial gut microbiota analysis by ultra-deep sequencing. J Hepatol 54:349
106. Aller R, de Luis DA, Izaola O et al (2011) Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 15:1090-1095
107. Zing X, Saxena NK, Lin S et al (2006) Exedin-4, a glucagon-like protein1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology 43:173-181
108. Buse JB, Klonoff DC, Nielsen LL (2007) Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 29:139-153
109. Jendle J, Nauck MA, Matthews DR et al (2009) Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 11:1163-1172
110. Ratziu V, Sheikh MY, Sanyal AJ et al (2011) A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology. doi:10.1002/hep.24747
111. Arase Y, Suzuki F, Ikeda K et al (2009) Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease. J Gastroenterol 44:1064-1070
112. Ristow M, Zarse K, Oberbach A et al (2009) Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci USA 106:8665-8670
113. Yfanti C, Akerström T, Nielsen S et al (2010) Antioxidant supplementation does not alter endurance training adaptation. Med Sci Sports Exerc 42:1388-1395
114. Yfanti C, Nielsen AR, Akerström T et al (2011) Effect of antioxidant supplementation on insulin sensitivity in response to endurance exercise training. Am J Physiol Endocrinol Metab 300:E761-E770
115. Miller ER, Pastor-Barriuso R et al (2005) Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142:37-46
116. Le KA, Ith M, Kreis R et al (2009) Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. Am J Clin Nutr 89:1760-1765
117. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R et al (2007) Long term nutritional intake and the risk for nonalcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 47:711-717
118. Assy N, Nasser G, Kamayse I et al (2008) Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Can J Gastroenterol 22:811-816
119. Ouyang X, Cirillo P, Sautin Y et al (2008) Fructose consumption as a risk factor for nonalcoholic fatty liver disease. J Hepatol 48:993-999
120. Abdelmalek MF, Suzuki A, Guy C et al (2010) Increased fructose consumption is associated with fibrosis severity in patients with NAFLD. Hepatology 51:1961-1971
121. Dunn W, Xu R, Schimmer JB (2008) Modest wine drinking and decreased prevalence of suspected non-alcoholic fatty liver disease. Hepatology 47:1947-1954
122. Cotrim HP, Freitas LA, Alves E et al (2009) Effects of light-to-moderate alcohol consumption on steatosis and steatohe-patitis in severely obese patients. Eur J Gastroenterol Hepatol 21:969-972
123. Ruhl CE, Everhart JE (2005) Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin Gastroenterol Hepatol 3:1260-1268
124. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN (2010) The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51:1972-1978
125. Hamabe A, Uto H, Imamura Y et al (2011) Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period. J Gastroenterol 46:769-778
126. Zein CO, Unalp A, Colvin R, Liu YC, McCullough AJ, Nonalcoholic Steatohepatitis Clinical Research Network (2011) Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol 54:753-759
127. Tsochatzis EA, Papatheodoridis GV (2010) Smoking is associated with histological severity in nonalcoholic steatohepatitis. Hepatology 52:1522-1523
128. Argo CK, Northup PG, Al-Osaimi AM et al (2009) Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 51:371-379
129. Chiang DJ, Pritchard MT, Nagy LE (2011) Obesity, diabetes mellitus, and liver fibrosis. Am J Physiol Gastrointest Liver Physiol 300:G697-G702
130. Musso G, Gambino R, Cassader M (2011) Need for a three-focused approach to nonalcoholic fatty liver disease. Hepatology 53:1773
131. Preiss D, Khunti K, Sattar N (2011) Combined cardiovascular and diabetes risk assessment in primary care. Diabet Med 28: 19-22
132. Silbernagel G, Grammer TB, Winkelmann BR, Boehm BO, März W (2011) Glycated hemoglobin predicts all-cause, cardiovascular, and cancer mortality in people without a history of diabetes undergoing coronary angiography. Diabetes Care. doi:10.2337/dc10-2010
133. Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M (2007) What is the best predictor of future type 2 diabetes? Diabetes Care 30:1544-1548
134. Musso G, Gambino R, Biroli G et al (2005) Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 100:2438-2446
135. Reddy KJ, Singh M, Bangit JR, Batsell RR (2010) The role of insulin resistance in the pathogenesis of atherosclerotic cardiovascular disease: an updated review. J Cardiovasc Med 11:633-647
136. Calori G, Lattuada G, Ragogna F et al (2011) Fatty liver index (FLI) and mortality: the Cremona study at the 15th year of follow up. Hepatology. doi:10.1002/hep.24356
137. Muniyappa R, Lee S, Chen H, Quon MJ (2008) Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 294:E15-E26
138. Devaraj S, Valleggi S, Siegel D, Jialal I (2010) Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome. Curr Atheroscler Rep 12:110-118
139. Musso G, Gambino R, Cassader M, Pagano G (2010) A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 52:79-104
140. Gambino R, Musso G, Cassader M (2011) Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. Antioxid Redox Signal 15:1325-1365